UTMD at a glance
UTAH MEDICAL PRODUCTS INC (UTMD, SEC CIK 706698) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 31, 2026 and Form 4 insider filings as recently as July 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), UTAH MEDICAL PRODUCTS INC (UTMD) reported revenue of $38.5 million (down 5.8% from FY2024) and net income of $11.3 million. Diluted EPS was $3.48.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding UTAH MEDICAL PRODUCTS INC (UTMD) shares worth $71.3 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $38.5M
- −5.8% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $71.3M · −1 vs prior quarter
- Latest 8-K
- Aug 31, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- 2Q revenue $8.529M, down 14.3% YoY from $9.953M
- Operating margin 31.1% vs 32.1%; net margin 31.5% vs 30.6%
- Best category: Obstetrics $1.066M, up from $1.025M; worst: Blood Pressure Monitoring $1.264M vs $2.019M
- Cash and investments $87.5M vs $85.8M; dividends $2.0M, buybacks $0.2M, capex $0.3M in 1H
- 2026 revenue guidance: down 10–13%; litigation expense estimate below $1.6M vs $1.355M in 2025
Risk Factors
- No risk-factors section provided in the filing excerpt
- 1,207 open-market shares repurchased during 2Q 2026 at average $64.10 per share
- Share repurchases depend on seller availability and stock price
- Repurchases lack an expiration date or maximum dollar or share limit
- Nasdaq listing preserved through restriction against terminating exchange eligibility
AI summary of the UTMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Femcare Ltd acquired all common shares of UK-based Orion Medical Supplies Ltd
- Transaction expands Utah Medical Products’ wholly owned subsidiary operations in the United Kingdom
Item EX-99.1: Item EX-99.1
- Femcare acquired all Orion Medical Supplies shares, expanding UTMD’s UK and European medical-device distribution
- Purchase price £3.6 million, funded from cash reserves
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results furnished under Item 2.02
- Exhibit 99.1 contains financial information for three and six months ended June 30, 2026
Item 99.1:
- Filing references a July 23, 2026 press release covering three and six months ended June 30, 2026
- Forward-looking statements address 2026 and beyond, making guidance and projections the key investor focus
Item EX-99.1: Item EX-99.1
- 2Q revenue fell 14.3% to $8.529M; 1H revenue declined 12.3% to $17.252M
- Lost PendoTECH and China distributor sales drove $1.066M of 2Q and $1.923M of 1H revenue shortfall
Item 5.07: Submission of Matters to a Vote of Security Holders
- Ernst G. Hoyer elected director with 1,330,333 votes; 1,070,640 withheld
- James H. Beeson elected director with stronger support: 1,708,941 votes
AI summaries of UTMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for UTMD
Don't miss the next UTMD filing
- Alerts as it files. A push when UTMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut UTMD, by share count.
- Ask anything. An AI agent that reads every UTMD filing and answers with sources.
UTMD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| RICHINS PAUL O | G | Jun 29, 2026 | 150 | $73.07 |
| Koopman Brian | G | May 28, 2026 | 50 | $66.27 |
| Koopman Brian | A | Oct 31, 2025 | 500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $40.9M | $38.5M |
| Gross Profit | - | $24.1M | $22.0M |
| Operating Income | - | $13.6M | $11.4M |
| Net Income | - | $13.9M | $11.3M |
| Gross Margin | - | 59.0% | 57.1% |
| Op. Margin | - | 33.2% | 29.6% |
| Net Margin | - | 33.9% | 29.3% |
| Balance Sheet | |||
| Total Assets | $135.5M | $122.5M | $122.5M |
| Equity | $128.3M | $117.4M | $119.3M |
| ROE | - | 11.8% | 9.5% |
| Per Share | |||
| EPS | - | $3.96 | $3.48 |
| Cash Flow | |||
| Operating CF | - | $14.8M | $14.7M |
| CapEx | - | $230K | $371K |
Source: XBRL data in UTAH MEDICAL PRODUCTS INC (UTMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate UTMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $71.3M |
| Q1 2026 | 25 | $62.1M |
| Q4 2025 | 24 | $58.6M |
| Q3 2025 | 23 | $67.6M |
| Q2 2025 | 24 | $63.4M |
| Q1 2025 | 20 | $55.4M |
| Q4 2024 | 15 | $57.2M |
| Q3 2024 | 14 | $44.5M |
- Morgan Stanley+20.9K (+43%)
- BlackRock+16.0K (+9%)
- AQR Capital Management+4.7K (+46%)
- T. Rowe Price Group+3.6K (+20%)
- Vanguard Portfolio Management LLC+2.8K (+16%)
- Renaissance Technologies LLC−8.3K (-5%)
- Vanguard Capital Management LLC−4.0K (-3%)
- Goldman Sachs Group−3.8K (-31%)
- Bank of America Corp−675 (-14%)
- State Street Corp−465 (-1%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 169 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
UTMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 31, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 23, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | May 29, 2026 | - | - | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 8-K | Apr 23, 2026 | - | Analysis | - |
| 10-K | Mar 27, 2026 | Dec 31, 2025 | - | |
| 8-K | Jan 29, 2026 | - | - | |
| 4 | Nov 25, 2025 | - | - | |
| 10-Q | Nov 14, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 12, 2025 | Jun 30, 2025 | - | |
| SC 13G | Jul 17, 2025 | - | - | |
| 10-Q | May 15, 2025 | Mar 31, 2025 | - | |
| SC 13G | May 14, 2025 | - | - | |
| 10-K | Mar 26, 2025 | Dec 31, 2024 | - | |
| 10-Q | Nov 12, 2024 | Sep 30, 2024 | - | |
| SC 13G | Oct 31, 2024 | - | - | |
| 10-Q | Aug 9, 2024 | Jun 30, 2024 | - | |
| 10-Q | May 10, 2024 | Mar 31, 2024 | - | |
| 10-K | Mar 26, 2024 | Dec 31, 2023 | - | |
| 10-Q | Nov 13, 2023 | Sep 30, 2023 | - | |
| 10-Q | Aug 11, 2023 | Jun 30, 2023 | - | |
| 10-Q | May 5, 2023 | Mar 31, 2023 | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
UTMD SEC filings: frequently asked questions
Which institutions hold UTMD stock?
As of June 30, 2026, the largest UTAH MEDICAL PRODUCTS INC (UTMD) holders among the 13F filers tracked by SignalX were BlackRock ($14.1 million), Dimensional Fund Advisors ($13.7 million), Renaissance Technologies LLC ($12.1 million), Vanguard Capital Management LLC ($9.3 million), Morgan Stanley ($4.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was UTMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), UTAH MEDICAL PRODUCTS INC (UTMD) reported revenue of $38.5 million (down 5.8% from FY2024) and net income of $11.3 million. Diluted EPS was $3.48. The figures come from the XBRL data in the 10-K.
What did UTMD report in its latest 8-K?
UTAH MEDICAL PRODUCTS INC (UTMD) filed an 8-K on August 31, 2026 reporting Item 7.01 (Regulation FD Disclosure). Femcare Ltd acquired all common shares of UK-based Orion Medical Supplies Ltd.
What are the latest UTMD SEC filings?
UTAH MEDICAL PRODUCTS INC (UTMD) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 31, 2026 and a Form 4 insider filing on July 1, 2026.
What is UTMD's SEC CIK number?
UTAH MEDICAL PRODUCTS INC (UTMD)'s SEC Central Index Key (CIK) is 706698. EDGAR lists every UTMD filing under that number.
Ask anything about UTMD
The research agent reads UTMD's filings, financials, insider trades and 13F holders, then answers with sources.